News | Peripheral Artery Disease (PAD) | July 17, 2017

First Patient Treated in U.S. Feasibility Study of LimFlow Critical Limb Ischemia Device

Company also announces commencement of international post-market study of Percutaneous Deep Vein Arterialization (pDVA) System

First Patient Treated in U.S. Feasibility Study of LimFlow Critical Limb Ischemia Device

July 17, 2017 — LimFlow SA announced enrollment of the first patient in the U.S. feasibility study of the LimFlow Percutaneous Deep Vein Arterialization (pDVA) System. The novel, purely percutaneous device is designed for the treatment of end-stage critical limb ischemia (CLI) when all other revascularization efforts have been exhausted. The first patient was treated on July 5, 2017 at Metro Health - University of Michigan Health by Jihad A. Mustapha, M.D., FACC, FSCAI.

The feasibility study is a multi-center, prospective, single-arm study to be conducted at three U.S. centers encompassing 10 “no-option” CLI patients. Endpoints include amputation-free survival at one month, patency, limb salvage and wound healing. Subjects will be followed out to two years.  This clinical trial is the initial step towards a U.S. approval pathway for the LimFlow System.

“The only other disease with worse life expectancy than CLI is pancreatic cancer. Because of the mortality rate associated with amputations due to ischemia, a new approach to treat CLI is needed now more than ever.  In the LimFlow study, we hope to help patients with no other options that are on their way to amputation” said Mustapha, the study’s primary investigator.

The Paris-based medical device company also announced the initiation of a multicenter, prospective, single-arm post-market surveillance study, which will enroll up to 50 Rutherford Class 5 and 6 “no-option” patients in several CLI centers of excellence in Europe and Asia. Patients will be followed out to one year, and endpoints include amputation-free survival (AFS) and wound healing progression. Data collection is aligned with the U.S. feasibility study, allowing for a large comparable dataset for the use of the LimFlow System in this “no-option” CLI sub-group.

The LimFlow System is designed to restore perfusion to the ischemic foot, which may relieve rest pain, promote chronic wound healing, reduce major amputations and restore mobility for patients when used as part of a multi-disciplinary team approach. It uses proprietary ultrasound-guided catheters and covered nitinol stents to uniquely bypass diseased arteries and divert blood flow into the tibial vein to vascularize the ischemic foot.

For more information:

Related Content

Videos | Cath Lab | March 15, 2018
A discussion with Hitinder Gurm, M.D., MBBS, FACC, professor, internal medicine, and associate chief clinical officer
News | Cath Lab | February 27, 2018
The American College of Cardiology (ACC) and the Saudi Arabian Cardiac Interventional Society have partnered to...
News | Cath Lab | February 23, 2018
February 23, 2018 — CorFlow Therapeutics AG announced that the company will present new insights into the coronary mi
Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Overlay Init